Savitz Ryan sold $11.2M of DNTH

Dianthus Therapeutics, Inc. /DE/ (DNTH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 DIANTHUS THERAPEUTICS HIGHLIGHTS RECENT BUSINESS ACHIEVEMENTS AND REPORTS Q3 2026 FINANCIAL RESULTS Advancing a neuromuscular franchise with claseprubart, a highly potent, investigational classical pathway inhibitor, with best-in-disease potential across generalized

Dianthus Therapeutics (DNTH) reported Q2 2026 results, highlighting clinical trial progress. Claseprubart showed a 75% response rate in a Phase 3 trial for chronic inflammatory demyelinating polyneuropathy. The company also advanced trials for multifocal motor neuropathy and generalized myasthenia gravis. R&D costs rose to $48.7M, with a net loss of $50.2M. DNTH has $1.2B in cash, funding operations into 2030.

Dianthus Therapeutics, Inc. /DE/ (DNTH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 DIANTHUS THERAPEUTICS HIGHLIGHTS RECENT BUSINESS ACHIEVEMENTS AND REPORTS Q2 2026 FINANCIAL RESULTS Advancing a neuromuscular franchise with claseprubart, a highly potent investigational classical pathway inhibitor, with best-in-disease potential across generalized M

Dianthus Therapeutics (Nasdaq: DNTH) said it initiated the Phase 3 EMERGE trial of claseprubart in generalized myasthenia gravis (AChR+). The global, randomized, placebo-controlled study enrolls ~195 patients; claseprubart 300mg/2mL is dosed Q2W or Q4W vs placebo. Top-line results are expected in 2H’28.

JOBSON CHARLES E purchased 236,116 shares of JOINT Corp (JYNT) at $6.65 ($1.57M total) on 2026-11-09.

Juniper Investment Company, LLC purchased 689,803 indirectly-held shares of Orthofix Medical Inc. (OFIX) at an average of $7.40 ($7.04–$7.41, $5.11M total) across 2 trades over 2026-11-09 to 2026-11-11. Filed jointly with Bartholdson John A. (10% owner) and MICHAS ALEXIS P (10% owner).